BMS-986231 (Bristol-Myers Squibb/Ligand) Drug Overview 2018: A Second-Generation Prodrug That Chemically Breaks Down to Produce Nitroxyl (HNO) and an Inactive Byproduct - ResearchAndMarkets.com

DUBLIN--()--The "BMS-986231" report has been added to ResearchAndMarkets.com's offering.

BMS-986231 (Bristol-Myers Squibb/Ligand) is a second-generation prodrug that chemically breaks down to produce nitroxyl (HNO) and an inactive byproduct.

HNO is thought to have a dual mode of action, by improving cardiac function and acting as a vasodilator. Additionally, HNO is thought to enhance myocardial function by improving calcium cycling and also myofilament calcium sensitivity. Finally, HNO acts a vasodilator through activation of soluble guanylate cyclase and activation of potassium channels in vascular smooth muscle.

BMS-986231's proposed dual mode of action and good tolerability could be presented as an improvement over currently used phosphodiesterase III inhibitors and Simdax (levosimendan; Orion/Tenax Therapeutics). However, more clinical data are required in order to verify the mechanism and identify any possible safety issues. The potential to act as an inotropic agent and a potent vasodilator could result in significant uptake in a highly genericized acute decompensated heart failure market, but until more is known regarding safety, no clear conclusions can be made regarding this product.

Key Topics Covered

  1. Product Profiles
  2. BMS-986231: Acute Decompensated Heart Failure (ADHF)

List of Figures

Figure 1: BMS-986231 for ADHF - SWOT analysis

Figure 2: Drug assessment summary of BMS-986231 for ADHF

Figure 3: Drug assessment summary of BMS-986231 for ADHF

List of Tables

Table 1: BMS-986231 drug profile

Table 2: BMS-986231 Phase II data in ADHF

Table 3: BMS-986231 Phase II trials in ADHF

For more information about this report visit https://www.researchandmarkets.com/research/stw449/bms986231?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs